135 related articles for article (PubMed ID: 17825907)
1. Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.
Breccia M; Martelli M; Cannella L; Russo E; Finolezzi E; Stefanizzi C; Levi A; Frustaci A; Alimena G
Leuk Res; 2008 Feb; 32(2):353-5. PubMed ID: 17825907
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy.
Orciuolo E; Fazzi R; Galimberti S; Testi C; Azzara' A; Carulli G; Petrini M
Leuk Res; 2006 Mar; 30(3):349-53. PubMed ID: 16182365
[TBL] [Abstract][Full Text] [Related]
3. Favorable early response of secondary chronic myeloid leukemia to imatinib.
Waldman D; Weintraub M; Freeman A; Neumann Y; Rechavi G; Toren A
Am J Hematol; 2004 Apr; 75(4):217-9. PubMed ID: 15054813
[TBL] [Abstract][Full Text] [Related]
4. ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma.
Ferrario A; Radaelli F; Goldaniga M; F FG; Olivero B; Rossi F; Baldini L
Leuk Res; 2010 Oct; 34(10):e280-1. PubMed ID: 20605208
[No Abstract] [Full Text] [Related]
5. Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature.
Kata D; Mrówka-Kata K; Seweryn M; Pajak J; Najda J; Kyrcz-Krzemień S
Leuk Res; 2010 Sep; 34(9):e229-31. PubMed ID: 20359744
[No Abstract] [Full Text] [Related]
6. [A case of chronic myeloid leukemia following TS-1 therapy for advanced gastric cancer].
Higuchi M; Nishinaka H; Yamano Y
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2049-52. PubMed ID: 17197751
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
Ramanarayanan J; Dunford LM; Baer MR; Sait SN; Lawrence W; McCarthy PL
Leuk Res; 2006 Jun; 30(6):701-5. PubMed ID: 16330096
[TBL] [Abstract][Full Text] [Related]
8. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
[TBL] [Abstract][Full Text] [Related]
9. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
11. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
Kiguchi T; Tauchi T; Ohyashiki K
Rinsho Ketsueki; 2009 Jan; 50(1):52-4. PubMed ID: 19225231
[TBL] [Abstract][Full Text] [Related]
12. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.
Breccia M; Carmosino I; Russo E; Morano SG; Latagliata R; Alimena G
Eur J Haematol; 2005 Feb; 74(2):121-3. PubMed ID: 15654902
[TBL] [Abstract][Full Text] [Related]
13. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
Koca E; Sevimli F; Cetiner D; Haznedaroglu IC; Sayinalp N; Büyükasik Y; Goker H; Ozcebe O
Am J Hematol; 2007 Apr; 82(4):333. PubMed ID: 17094091
[No Abstract] [Full Text] [Related]
15. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
Palandri F; Iacobucci I; Castagnetti F; Testoni N; Poerio A; Amabile M; Breccia M; Intermesoli T; Iuliano F; Rege-Cambrin G; Tiribelli M; Miglino M; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M;
Haematologica; 2008 May; 93(5):770-4. PubMed ID: 18367490
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Kantarjian H; O'Brien S; Shan J; Huang X; Garcia-Manero G; Faderl S; Ravandi-Kashani F; Verstovsek S; Beth Rios M; Cortes J
Cancer; 2008 Feb; 112(4):837-45. PubMed ID: 18085610
[TBL] [Abstract][Full Text] [Related]
17. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
[TBL] [Abstract][Full Text] [Related]
18. Insufficient outcomes with imatinib mesylate: case report of Ph-positive acute myeloid leukemia evolving from myelodysplastic syndrome.
Isoda A; Nakahashi H; Hoshino T; Mitsui T; Yoshida Y
Am J Hematol; 2007 Jun; 82(6):501-2. PubMed ID: 17301971
[No Abstract] [Full Text] [Related]
19. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
[TBL] [Abstract][Full Text] [Related]
20. Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
Ahmed MS; Kroft SH; Davis NB; King DM; Cheng YC
Leuk Res; 2008 Sep; 32(9):1476-9. PubMed ID: 18308388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
